Abstract
444PD - Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have